Original Research
Antipruritic Hydrogel for the Treatment of Atopic Dermatitis: An Open-Label Pilot Study
Cutis. 2012 August;90(2):97-102
By
Draelos ZD
Author and Disclosure Information
Draelos ZD
![](/sites/all/themes/custom/medstat_cutis/img/logo.png)
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in industrialized nations. The efficacy and tolerability of Atrapro (RD047-26) antipruritic hydrogel was evaluated in 17 adult participants with mild to moderate AD with associated pruritus. The antipruritic hydrogel was applied 3 times daily to the affected areas of the body, and participants were evaluated on days 3, 7, and 14 (end of study). There were 3 efficacy end points: investigator global assessment (IGA), investigator pruritus assessment (IPA), and participant itch assessment (PIA). All 3 efficacy end points were met and showed a statistically significant improvement in the mean score from baseline to day 14 (P